Related references
Note: Only part of the references are listed.Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants
Robert A. Smith et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Insertion as a Resistance Mechanism Against Integrase Inhibitors in Several Retroviruses
Hanh Thi Pham et al.
CLINICAL INFECTIOUS DISEASES (2019)
A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain
Quentin Le Hingrat et al.
CLINICAL INFECTIOUS DISEASES (2019)
Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes
Koen K. A. Van Rompay et al.
JOURNAL OF VIROLOGY (2019)
In Vitro Antiviral Activity of Cabotegravir against HIV-2
Robert A. Smith et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2
Robert A. Smith et al.
RETROVIROLOGY (2015)
Three Main Mutational Pathways in HIV-2 Lead to High-Level Raltegravir and Elvitegravir Resistance: Implications for Emerging HIV-2 Treatment Regimens
Robert A. Smith et al.
PLOS ONE (2012)
Hot Spots of Integrase Genotypic Changes Leading to HIV-2 Resistance to Raltegravir
Charlotte Charpentier et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Share Paper
